BioSpecifics Technologies Corp

Entity type image
Type: Company
Name: BioSpecifics Technologies Corp
First reported May 15 2013 - Updated May 15 2013 - 1 reports

BioSpecifics Technologies Price Target Cut to $20.00 by Analysts at MKM Partners (BSTC)

BioSpecifics Technologies (NASDAQ: BSTC) had its price target decreased by MKM Partners from $21.00 to $20.00 in a research report released on Monday morning, Analyst Ratings Network reports. MKM Partners currently has a buy rating on the stock.Separately, ... [Published Mideast Time - May 15 2013]
First reported May 13 2013 - Updated May 14 2013 - 2 reports
New York Stock Exchange
New York Stock Exchange

Company News for May 13, 2013 - Corporate Summary

â¢Â   DiamondRock Hospitality Company (NYSE: DRH ) posted first quarter earnings per share of $0.14, ahead of the Zacks Consensus Estimate of $0.09 â¢Â   BioSpecifics Technologies Corp. (NASDAQ: BSTC ) reported first quarter earnings per share of ... [Published Nasdaq - May 13 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports

BioSpecifics Technologies Given New $20.00 Price Target at MKM Partners (BSTC)

MKM Partners lowered their price target on shares of BioSpecifics Technologies (NASDAQ: BSTC)Separately, analysts at Aegis reiterated a ?buy? rating on shares of BioSpecifics Technologies in a research note to investors on Monday, March 11th.Shares of ... [Published American Banking News - May 14 2013]
First reported May 10 2013 - Updated May 10 2013 - 5 reports
Phase II
Phase II

BioSpecifics Technologies' Management Discusses Q1 2013 Results - Earnings Call Transcript

BioSpecifics Technologies Corp. (BSTC) Q1 2013 Earnings Call May 10, 2013 8:30 AM ETOperatorThank you for holding. Welcome to the BioSpecifics’ Q1 2013 Financial Results Conference Call. (Operator instructions.) I would like to introduce your host for ... [Published Seeking Alpha - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 2 reports

BioSpecifics Technologies Corporation Reports First Quarter 2013 Financial Results

/PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(R) in the U.S., announced today that it will host a conference call and live audio webcast ... [Published BioSpace - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

BioSpecifics Technologies (BSTC) Posts Quarterly Earnings, Beats Estimates By $0.01 EPS

BioSpecifics Technologies (NASDAQ: BSTC) announced its earnings results on Friday. The company reported $0.19 earnings per share for the quarter, beating the analysts? consensus estimate of $0.18 by $0.01, reports. On the ratings front, analysts at Aegis ... [Published American Banking News - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

BioSpecifics (BTSC): Q1 EPS of $0.19 beats by $0.05. Revenue of $3.98M beats by $0.83M. (PR)

:08 AM ET BioSpecifics (BTSC): Q1 EPS of $0.19 beats by $0.05. Revenue of $3.98M beats by $0.83M. (PR) ... [Published Seeking Alpha - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

U.S./Canada daily earnings hits & misses May 10 - 0800 ET

May 10 (Reuters) - The following U.S.- and Canada-listed companies reported earnings on Friday. This list shows whether they beat, met or missed Wall Street analysts' forecasts. It also shows the difference between analysts' expectations and reported ... [Published Globe and Mail - May 10 2013]
First reported May 03 2013 - Updated May 03 2013 - 3 reports

BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013

LYNBROOK, N.Y.In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website ... [Published Bio-Medicine - May 03 2013]
First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

8-K - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Filer)

Filed: 2013-04-19 AccNo: 0001062993-13-001980 Size: 2 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits ... [Published SEC Filings - Apr 19 2013]
First reported Apr 10 2013 - Updated Apr 10 2013 - 1 reports

8-K - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Filer)

Filed: 2013-04-10 AccNo: 0001062993-13-001790 Size: 2 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits ... [Published SEC Filings - Apr 10 2013]
First reported Jan 07 2013 - Updated Jan 08 2013 - 2 reports

Auxilium Pharma expands exclusive license with BioSpecifics for CCH to include potential treatment of cellulite as additional indication

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, has exercised its exclusive option under the Second Amended and Restated Development and License Agreement (CCH License Agreement), dated as of August 31, 2011, with BioSpecifics ... [Published PharmaBiz - Jan 08 2013]

Quotes

"We are very pleased to have completed enrollment in our Phase II trials in canine and human lipoma and we remain on track to report top-line data for both trials in the second half of this year" reflected Thomas L Wegman, President of BioSpecifics. $ First Quarter 2013 Financial Results
BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 10 2013]
...we remain on track to report top-line data for both trials in the second half of this year," reflected Thomas L Wegman, President of BioSpecifics. "In addition, there are a number of exciting upcoming milestones for XIAFLEX this year. We are looking forward to the potential approval of XIAFLEX for the treatment of Peyronie's Disease in the third quarter of this year and if approved, we would anticipate the U S commercial launch in this indication in the fourth quarter of 2013. We are also eagerly awaiting the initiation of a new clinical trial for XIAFLEX in frozen shoulder syndrome in the second half of this year, following the announcement of the statistically significant top-line data from the Phase IIa study, as well as the initiation of a Phase II study in the cellulite indication during the same time period. Finally we believe there is tremendous potential for XIAFLEX in the treatment of many medical conditions caused by excess collagen accumulation and BioSpecifics will continue to devote its efforts to the development in new clinical indications in the future."
BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results [Published NewsBlaze - May 10 2013]
"While cellulite isn't harmful, it is a serious cosmetic concern for many people who want to feel better about their appearance and who want to reduce cellulite as much as possible. There are many methods to remove cellulite but few have been supported in medical literature to be effective or potentially usable as a standard practice" the specialist explained
Stony Brook University to begin clinical trials for cellulite treatment [Published Labmate Online - Apr 17 2013]
"We are very encouraged by these positive results and look forward to progress in this program which Auxilium expects in the second half of this year" reflected Thomas L Wegman This open-label, controlled dose-ranging Phase IIa study was conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals...
BioSpecifics Technologies Corp. Announces Positive Top-line Data from XIAFLEX® Phase IIa Study fo ... [Published PR Newswire - Mar 26 2013]

More Content

All (58) | News (46) | Reports (2) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (10)
sort by: Date | Relevance
BioSpecifics Technologies Price Target Cut to $... [Published Mideast Time - May 15 2013]
BioSpecifics Technologies Given New $20.00 Pric... [Published American Banking News - May 14 2013]
Company News for May 13, 2013 - Corporate Summary [Published Nasdaq - May 13 2013]
Company News for May 13, 2013 Zacks [Published Yahoo! Finance - May 13 2013]
BioSpecifics Technologies' Management Discusses... [Published Seeking Alpha - May 10 2013]
BioSpecifics Technologies Corporation Reports F... [Published BioSpace - May 10 2013]
U.S./Canada daily earnings hits & misses May 10... [Published Globe and Mail - May 10 2013]
BioSpecifics Technologies Corporation (BSTC) Re... [Published BioSpace - May 10 2013]
BioSpecifics Technologies (BSTC) Posts Quarterl... [Published American Banking News - May 10 2013]
BioSpecifics (BTSC): Q1 EPS of $0.19 beats by $... [Published Seeking Alpha - May 10 2013]
U.S./Canada daily earnings hits & misses May 10... [Published Globe and Mail - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Yahoo! Finance - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published NewsBlaze - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published ADVFN UK - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Staten Island Live - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published PR Newswire: Financial Services - May 10 2013]
Earnings Scheduled For May 10, 2013 [Published Benzinga.com - May 10 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published Bio-Medicine - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published FinanzNachrichten.de - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published WTNZ - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - May 03 2013]
Auxilium Pharmaceuticals, Inc. (AUXL), AbbVie I... [Published InsiderMonkey.com - May 01 2013]
DEF 14A - BIOSPECIFICS TECHNOLOGIES CORP (00008... [Published SEC - Apr 30 2013]
8-K - BIOSPECIFICS TECHNOLOGIES CORP (000087562... [Published SEC Filings - Apr 19 2013]
Stony Brook University to begin clinical trials... [Published Labmate Online - Apr 17 2013]
Clinical Trials for Cellulite Treatment on the ... [Published Newswise - Apr 16 2013]
8-K - BIOSPECIFICS TECHNOLOGIES CORP (000087562... [Published SEC Filings - Apr 10 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire - Mar 26 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Mar 26 2013]
8-K - BIOSPECIFICS TECHNOLOGIES CORP (000087562... [Published SEC Filings - Mar 13 2013]
1 2
In Focus
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
BioSpecifics Technologies Corp. Reports First Q... [Published PR Newswire: Financial Services - May 10 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - May 03 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire - Mar 26 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Mar 26 2013]
BioSpecifics Technologies Corp. Reports Fourth ... [Published Financial Services - Mar 12 2013]
1 2
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.